Patient Invoice Payment Link
Contact Us

Advanced Mini Vaginitis PCR Panel

Comprehensive, Rapid, and Clinically Actionable Detection

Redefining Vaginal Infection Diagnosis

Vaginal infections are among the most common clinical complaints—but also among the most misdiagnosed and recurrent due to:

  • Overlapping symptoms between BV, candidiasis, and trichomoniasis
  • Limitations of microscopy and culture
  • Incomplete understanding of the vaginal microbiome
  • Rising antimicrobial resistance

Our multiplex Vaginitis PCR Panel delivers rapid, highly sensitive detection of pathogens, microbiome balance, and resistance markers—supporting accurate diagnosis and targeted treatment.

Mini Vaginitis Panel

Bacteria
8 targets
Atopobium vaginae
Bac (gram-positive)
Bacterial Vaginosis-Associated Bacterium 2
Bac (gram-variable)
Enterococcus faecalis
Bac (gram-positive)
Gardnerella vaginalis
Bac (gram-negative)
Lactobacillus spp. (crispatus/ reuteri/ gasseri/ vaginalis/ jensenii/ iners)
Bac (gram-variable)
Megasphaera type I
Bac (gram-negative)
Megasphaera type II
Bac (gram-positive)
Mobiluncus Mulieris
Bac (gram-negative)
Fungus
2 targets
Candida glabrata
Fungus
Candida spp. (albicans/tropicalis/parapsilosis/dubliniensis)
Fungus
Protozoal
1 targets
Trichomonas vaginalis
Protozoal
AMR
17 targets
Class A beta-lactamase resistance (blaSHV)
AMR
Class A beta-lactamase resistance (blaTEM)
AMR
Class A beta-lactamase resistance (CTX-M-Grp1)
AMR
Class B beta-lactamase resistance (blaNDM-1/blaNDM-4/blaNDM-5/blaNDM-7)
AMR
Class D beta-lactamase resistance (OXA-48/OXA-51)
AMR
Fluconazole resistance (ERG11)
AMR
Fluoroquinolone resistance (gyrA)
AMR
Fluoroquinolone resistance (qnrA/qnrB/qnrS)
AMR
Methicillin resistance (mecA)
AMR
Nitrofurantoin resistance (nfsA/nfsB)
AMR
Sulfonamide resistance (sul1)
AMR
Tetracycline resistance (tetB)
AMR
Tetracycline resistance (tetM)
AMR
Trimethoprim resistance (dfrA1)
AMR
Vancomycin resistance (vanA)
AMR
Vancomycin resistance (vanB)
AMR
Vancomycin resistance (vanM)
AMR

Comprehensive Pathogen & Microbiome Coverage

Bacterial Pathogens & BV-Associated Organisms

Detects key organisms driving bacterial Vaginitis and dysbiosis:

  • Gardnerella vaginalis
  • Atopobium vaginae
  • BV-associated bacteria (e.g., BVAB-2)
  • Megasphaera types I & II
  • Mobiluncus curtisii & mulieris
  • Prevotella bivia

Also includes clinically relevant organisms:

  • Staphylococcus aureus
  • Streptococcus agalactiae (Group B)
  • Escherichia coli

Full bacterial panel outlined on page 1

Vaginal Microbiome Balance Indicators

  • Lactobacillus spp. (crispatus, gasseri, jensenii, etc.)

Helps assess:

  • Healthy vs. dysbiotic vaginal environment
  • Risk of recurrence
  • Need for microbiome restoration strategies

Fungal Pathogens (Candidiasis)

  • Candida albicans
  • Candida glabrata
  • Candida tropicalis
  • Emerging pathogen: Candida auris

Fungal targets detailed on page 1

Protozoal Infection

  • Trichomonas vaginalis

A common but often underdiagnosed STI

Integrated Antimicrobial Resistance (AMR) Detection

Provides critical insight into treatment failure risk:

  • Beta-lactam resistance: blaTEM, blaSHV, CTX-M
  • Carbapenem resistance: NDM variants, OXA-48/51
  • Fluconazole resistance: ERG11
  • Fluoroquinolone resistance: gyrA, qnr genes
  • Methicillin resistance: mecA
  • Nitrofurantoin resistance: nfsA/nfsB
  • Additional resistance markers: sul1, tetB, tetM, dfrA1, van genes

AMR targets detailed across pages 1–2

All targets confirmed from the attached panel specification

Clinical Utility — Why This Panel Matters

1. Differentiates Overlapping Vaginal Conditions

Accurately distinguishes between:

  • Bacterial Vaginitis (BV)
  • Vulvovaginal candidiasis (VVC)
  • Trichomoniasis
  • Mixed infections

Eliminates guesswork and improves treatment precision

2. Detects Polymicrobial Infections

  • Many cases involve multiple pathogens simultaneously
  • PCR enables comprehensive detection in a single test

3. Provides Insight into Vaginal Microbiome Health

  • Identifies imbalance between:
  • Protective Lactobacillus species
  • Pathogenic anaerobes
  • Supports:
  • Recurrence prevention strategies
  • Probiotic or microbiome-directed therapy

4. Improves Accuracy Over Traditional Methods

  • Traditional methods (wet mount, culture):
  • Limited sensitivity
  • Operator-dependent
  • Often miss fastidious organisms
  • PCR provides:
  • Higher sensitivity and specificity
  • Detection of low-abundance and non-culturable organisms
  • Results in ~24 hours

5. Guides Targeted Therapy with AMR Detection

  • Identifies resistance markers impacting:
  • Antibiotics
  • Antifungals (e.g., fluconazole resistance)
  • Enables:
  • Personalized treatment plans
  • Reduced treatment failure
  • Improved antimicrobial stewardship

6. Reduces Recurrence and Chronic Symptoms

  • Addresses underlying microbiome imbalance
  • Identifies missed co-infections
  • Supports more durable clinical resolution

Clinical Scenarios Where This Panel Excels

Recurrent vaginitis with unclear etiology

Persistent symptoms despite treatment

Negative or inconclusive microscopy/culture

Suspected mixed infections

High-risk or complex patients

Key Advantages at a Glance

Broad pathogen detection (bacteria + fungi + protozoa)

Vaginal microbiome insight

Integrated AMR profiling

Rapid turnaround (~24 hours)

Detects polHigh sensitivity vs. traditional methodsymicrobial infections

Supports precision treatment

Elevating Women’s Health Through Precision Diagnostics

This Vaginitis PCR Panel empowers providers to:

Deliver accurate, evidence-based diagnoses

Prescribe targeted, effective therapies

Reduce recurrence and chronic infection burden

Improve patient satisfaction and outcomes